Work with thought leaders and academic experts in cancer research

Companies can greatly benefit from working with experts in the field of Cancer Research. These researchers bring a deep understanding of the disease and its mechanisms, allowing them to contribute valuable insights and expertise. Here are some ways companies can collaborate with academic researchers in Cancer Research: 1. Drug Discovery and Development: Academic researchers can assist in the discovery and development of new cancer drugs, providing expertise in target identification, preclinical testing, and clinical trials. 2. Biomarker Identification: Researchers can help identify biomarkers that can be used for early cancer detection, patient stratification, and monitoring treatment response. 3. Genomic Analysis: Experts in Cancer Research can analyze genomic data to identify genetic mutations and variations associated with cancer, enabling personalized treatment approaches. 4. Translational Research: Collaboration with academic researchers can facilitate the translation of basic research findings into clinical applications, bridging the gap between bench and bedside. 5. Clinical Trials: Companies can partner with academic researchers to conduct clinical trials, leveraging their expertise in trial design, patient recruitment, and data analysis. 6. Data Analytics: Researchers can apply advanced data analytics techniques to large-scale cancer datasets, uncovering patterns and insights that can inform treatment strategies. 7. Collaborative Research Projects: Joint research projects between companies and academic researchers can lead to innovative solutions and breakthrough discoveries in cancer treatment and prevention. 8. Education and Training: Academic researchers can provide educational programs and training to company employees, keeping them updated on the latest advancements in Cancer Research. 9. Intellectual Property: Collaboration with academic researchers can result in the generation of intellectual property, including patents and publications, which can enhance a company's competitive advantage. 10. Access to Networks and Resources: Academic researchers have access to extensive networks and resources, including collaborations with other experts, funding opportunities, and state-of-the-art facilities.

Experts on NotedSource with backgrounds in cancer research include Ramy Ayoub, Michael W Harman, Boris Leibovitch, Jeffrey Townsend, Edoardo Airoldi, Lee Weinstein, Jennifer Aaker, Liam D. Hendrikse, Ph.D., Giuliana Noratto, Marina Baretti, Ramy Ayoub, Timothy Sears, Katelyn Katelyn Masiuk, Jens Hegg, Kayvan Najarian, Amir Manbachi, Dona SLEIMAN, Olivier Saulnier, AMAN SHARMA, Ernesto Lowy, Niko Popitsch, and PRABIN KUMAR MAJHI.

Ramy Ayoub

Toronto, Ontario, Canada
PhD Candidate Medical Biophysics
Most Relevant Research Interests
Cancer Research
Cancer Research
Other Research Interests (17)
neuro-oncology
mouse imaging
cancer therapy
normal tissue toxicity
Multidisciplinary
And 12 more
About
Ramy Ayoub is a PhD candidate at the University of Toronto in the department of Medical Biophysics. His research focuses on the development of treatment strategies to limit long-term negative complications in brain tumour survivors treated with radiation therapy. Ramy addresses his thesis work by conducting genetic, pharmacological, and neuroimaging studies on mouse models for paediatric radiotherapy. Ramy has authored numerous scientific publications and is a recipient of several awards, including the Brain Star award for excellence in Canadian research. Ramy has passion for advancing science innovation through collaborative efforts across academia and industry.
Most Relevant Publications (2+)

7 total publications

QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma

Neuro-Oncology / Jun 01, 2022

Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452

Michael W Harman

East Greenwich, RI, Rhode Island, United States of America
Distinguished Subject Matter Expert & Leader in Medical Technologies.
Most Relevant Research Interests
Cancer Research
Other Research Interests (16)
Bacteria & Cell Bio-Physics
Biomechanics
Infectious Diseases
Immunology
Microbiology
And 11 more
About
Highly skilled, energetic, and motivated professional empowered by over a decade of cross-disciplinary engineering and scientific applications experience. Presenting elegant solutions to prevalent biomedical challenges. Motivated by driving deliverable outcomes from complex research studies through effective leadership, active consulting work, and innovative problem-solving techniques. Seeking to make an immediate impact in a fast-paced biotechnology environment capitalizing on my advanced comprehension, continued professional growth, strategic product development expertise, and active network of personal connections across all areas of science, engineering, medicine, manufacturing and healthcare.
Most Relevant Publications (3+)

15 total publications

The induction of endoreduplication and polyploidy by elevated expression of 14-3-3γ

Genes & Cancer / Dec 24, 2017

Gomes, C. J., Centuori, S. M., Harman, M. W., Putnam, C. W., Wolgemuth, C. W., & Martinez, J. D. (2017). The induction of endoreduplication and polyploidy by elevated expression of 14-3-3γ. Genes & Cancer, 8(11–12), 771–783. https://doi.org/10.18632/genesandcancer.161

Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells

Cancer Research / Jul 15, 2016

Gomes, C. J., Harman, M., Centuori, S., Wolgemuth, C., & Martinez, J. (2016). Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells. Cancer Research, 76(14_Supplement), 3591–3591. https://doi.org/10.1158/1538-7445.am2016-3591

Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers

Cancer Research / Aug 01, 2015

Gomes, C. J., Harman, M., Martinez, J., & Centuori, S. (2015). Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers. Cancer Research, 75(15_Supplement), 2066–2066. https://doi.org/10.1158/1538-7445.am2015-2066

Boris Leibovitch

New York, New York, United States of America
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Interests
Cancer Research
Other Research Interests (11)
Cell Biology
Developmental Biology
Molecular Biology
Multidisciplinary
Hematology
And 6 more
About
I am experienced molecular and cell biologist with deep genetics background who worked many years in USA and Russia on the bench and as teacher. Both types of work had demanded extremely broad knowledge and understanding of developments in the fields. Participation in grant writing, editorial/reviewer work for scientific journals and consulting colleagues on these subjects added a lot to my broad experience as the scientist.
Most Relevant Publications (2+)

22 total publications

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Molecular Cancer Therapeutics / Aug 01, 2015

Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t

Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1

Translational Oncology / Feb 01, 2022

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320

Jeffrey Townsend

New Haven, CT
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Cancer Research
Other Research Interests (78)
Statistics
cancer genetics
disease modeling
antibiotic resistance
Evolutionary Genomics
And 73 more
About
Jeffrey Townsend is a Professor of Organismic and Evolutionary Biology at Yale University. He received his Ph.D. from Harvard University in 2002 and his Sc.B. from Brown University in 1994. He has been a teacher at St. Ann's School and an Assistant Professor at the University of Connecticut. He is currently the Elihu Professor of Biostatistics at Yale University.
Most Relevant Publications (18+)

207 total publications

Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR

Cancer Research / Dec 05, 2022

Mandell, J. D., Cannataro, V. L., & Townsend, J. P. (2022). Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR. Cancer Research, 83(4), 500–505. https://doi.org/10.1158/0008-5472.can-22-1508

Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia

Leukemia / Nov 11, 2022

Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5

Cancer Relevance of Human Genes

JNCI: Journal of the National Cancer Institute / Apr 13, 2022

Qing, T., Mohsen, H., Cannataro, V. L., Marczyk, M., Rozenblit, M., Foldi, J., Murray, M., Townsend, J. P., Kluger, Y., Gerstein, M., & Pusztai, L. (2022). Cancer Relevance of Human Genes. JNCI: Journal of the National Cancer Institute, 114(7), 988–995. https://doi.org/10.1093/jnci/djac068

Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma

Cancer Letters / Feb 01, 2022

Fisk, J. N., Mahal, A. R., Dornburg, A., Gaffney, S. G., Aneja, S., Contessa, J. N., Rimm, D., Yu, J. B., & Townsend, J. P. (2022). Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 526, 346–351. https://doi.org/10.1016/j.canlet.2021.11.011

Environmental and sex-specific molecular signatures of glioma causation

Neuro-Oncology / May 04, 2021

Claus, E. B., Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2021). Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology, 24(1), 29–36. https://doi.org/10.1093/neuonc/noab103

Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden

Lung Cancer / Apr 01, 2022

Tan, C., Mandell, J. D., Dasari, K., Cannataro, V. L., Alfaro-Murillo, J. A., & Townsend, J. P. (2022). Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden. Lung Cancer, 166, 265–269. https://doi.org/10.1016/j.lungcan.2021.10.008

Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma

Oral Oncology / Feb 01, 2020

Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. (2020). Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. Oral Oncology, 101, 104554. https://doi.org/10.1016/j.oraloncology.2019.104554

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

Clinical Cancer Research / Jun 01, 2019

Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D., Zhu, F., Mehra, R., Sharma, R., Gaffney, S. G., Perry, E. B., Townsend, J. P., Serebriiskii, I. G., Golemis, E. A., Issaeva, N., Yarbrough, W. G., Koo, J. S., & Burtness, B. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 25(11), 3430–3442. https://doi.org/10.1158/1078-0432.ccr-18-0440

APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma

Oncogene / Jan 15, 2019

Cannataro, V. L., Gaffney, S. G., Sasaki, T., Issaeva, N., Grewal, N. K. S., Grandis, J. R., Yarbrough, W. G., Burtness, B., Anderson, K. S., & Townsend, J. P. (2019). APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Oncogene, 38(18), 3475–3487. https://doi.org/10.1038/s41388-018-0657-6

Wagging the long tail of drivers of prostate cancer

PLOS Genetics / Jan 17, 2019

Cannataro, V. L., & Townsend, J. P. (2019). Wagging the long tail of drivers of prostate cancer. PLOS Genetics, 15(1), e1007820. https://doi.org/10.1371/journal.pgen.1007820

Somatic evolutionary timings of driver mutations

BMC Cancer / Jan 18, 2018

Gomez, K., Miura, S., Huuki, L. A., Spell, B. S., Townsend, J. P., & Kumar, S. (2018). Somatic evolutionary timings of driver mutations. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-017-3977-y

Effect Sizes of Somatic Mutations in Cancer

JNCI: Journal of the National Cancer Institute / Oct 26, 2018

Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018). Effect Sizes of Somatic Mutations in Cancer. JNCI: Journal of the National Cancer Institute, 110(11), 1171–1177. https://doi.org/10.1093/jnci/djy168

Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C

Oncogene / Feb 16, 2018

Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M., Greenstein, A. E., & Townsend, J. P. (2018). Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. Oncogene, 37(18), 2444–2455. https://doi.org/10.1038/s41388-017-0105-z

CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma

Frontiers in Oncology / Apr 04, 2018

Chen, W. S., Bindra, R. S., Mo, A., Hayman, T., Husain, Z., Contessa, J. N., Gaffney, S. G., Townsend, J. P., & Yu, J. B. (2018). CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00095

The ancestral levels of transcription and the evolution of sexual phenotypes in filamentous fungi

PLOS Genetics / Jul 13, 2017

Trail, F., Wang, Z., Stefanko, K., Cubba, C., & Townsend, J. P. (2017). The ancestral levels of transcription and the evolution of sexual phenotypes in filamentous fungi. PLOS Genetics, 13(7), e1006867. https://doi.org/10.1371/journal.pgen.1006867

PhyloOncology: Understanding cancer through phylogenetic analysis

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer / Apr 01, 2017

Somarelli, J. A., Ware, K. E., Kostadinov, R., Robinson, J. M., Amri, H., Abu-Asab, M., Fourie, N., Diogo, R., Swofford, D., & Townsend, J. P. (2017). PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1867(2), 101–108. https://doi.org/10.1016/j.bbcan.2016.10.006

Inferring the Origin of Metastases from Cancer Phylogenies

Cancer Research / Sep 30, 2015

Hong, W. S., Shpak, M., & Townsend, J. P. (2015). Inferring the Origin of Metastases from Cancer Phylogenies. Cancer Research, 75(19), 4021–4025. https://doi.org/10.1158/0008-5472.can-15-1889

Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets

International Journal of Radiation Oncology*Biology*Physics / May 01, 2017

Chen, W. S., Townsend, J. P., & Yu, J. B. (2017). Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. International Journal of Radiation Oncology*Biology*Physics, 98(1), 8–10. https://doi.org/10.1016/j.ijrobp.2017.01.023

Edoardo Airoldi

Liam D. Hendrikse, Ph.D.

Toronto, Ontario, Canada
Bioinformatician at the University Health Network in Toronto, CA, specializing in computational cancer research using various sequencing modalities.
Most Relevant Research Interests
Cancer Research
Cancer Research
Other Research Interests (13)
Medulloblastoma
Bioinformatics
Genomics
Multidisciplinary
General Biochemistry, Genetics and Molecular Biology
And 8 more
About
Liam Hendrikse is a recent Ph.D. graduate from the Department of Medical Biophysics at the University of Toronto, now working as a Bioinformatician at the University Health Network. His research focuses on deepening our understanding of various cancer types using computational methods, in order to develop novel treatment options. Liam has a particular strength in analysis of various single-cell sequencing technologies (RNA, ATAC, CITE, TCR/BCR, etc.), as well as traditional sequencing technologies, such as bulk RNAseq. Liam has a proven track record of deriving highly impactful biological insights through his research, as evidenced by publications in high impact journals such as Nature and Cancer Discovery. Previously, Liam earned his Bachelor of Science in biochemistry and immunology from Western University in 2018.
Most Relevant Publications (3+)

10 total publications

MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS

Neuro-Oncology / Jun 01, 2023

Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hou, E., Hendrikse, L., Wang, L., Husain, S., Beytagh, M. C., Schmidt, C., Huang, M., Taylor, M., & Weiss, W. (2023). MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS. Neuro-Oncology, 25(Supplement_1), i62–i63. https://doi.org/10.1093/neuonc/noad073.240

MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA

Neuro-Oncology / Jun 01, 2023

Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254

DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA

Neuro-Oncology / Nov 01, 2022

Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hendrikse, L., Taylor, M., & Weiss, W. (2022). DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii106–vii106. https://doi.org/10.1093/neuonc/noac209.398

Giuliana Noratto

Food Scientist PhD and Registered Dietician - Texas A&M University
Most Relevant Research Interests
Cancer Research
Other Research Interests (49)
Food Science
human nutrition
disease prevention and treatment
Nutrition
Human Health
And 44 more
About
Dr. Giuliana Noratto is a senior associate research scientist at Texas A&M AgriLife. She received her Ph.D. in food science and technology from Texas A&M University System, and her M.Sc. in food science and technology from Universidad Nacional Agraria La Molina. She also holds a B.S. in food science and technology from Universidad Nacional Agraria La Molina. Dr. Noratto’s research interests include food safety and quality, sensory science, and food processing.
Most Relevant Publications (4+)

91 total publications

Calotropis Procera Induced Caspase-Dependent Apoptosis and Impaired Akt/mTOR Signaling in 4T1 Breast Cancer Cells

Anti-Cancer Agents in Medicinal Chemistry / Nov 01, 2022

Rabelo, A. C. S., Miglino, M. A., Arbizu, S., Carreira, A. C. O., Filho, A. J. C., Carneiro, F. J. C., Layosa, M. A. A., & Noratto, G. (2022). Calotropis Procera Induced Caspase-Dependent Apoptosis and Impaired Akt/mTOR Signaling in 4T1 Breast Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 22(18), 3136–3147. https://doi.org/10.2174/1871520622666220608122154

Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation

Nutrition and Cancer / Sep 14, 2020

Layosa, M. A. A., Lage, N. N., Chew, B. P., Atienza, L., Mertens-Talcott, S., Talcott, S., & Noratto, G. D. (2020). Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation. Nutrition and Cancer, 73(10), 1985–1997. https://doi.org/10.1080/01635581.2020.1817514

Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells

Nutrition and Cancer / Oct 20, 2014

Dias, M. M. dos S., Noratto, G., Martino, H. S. D., Arbizu, S., Peluzio, M. do C. G., Talcott, S., Ramos, A. M., & Mertens-Talcott, S. U. (2014). Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells. Nutrition and Cancer, 66(8), 1394–1405. https://doi.org/10.1080/01635581.2014.956252

Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10

Molecular Carcinogenesis / Mar 07, 2012

Mertens-Talcott, S. U., Noratto, G. D., Li, X., Angel-Morales, G., Bertoldi, M. C., & Safe, S. (2012). Betulinic acid decreases ER-negative breast cancer cell growth in vitro and in vivo: Role of Sp transcription factors and microRNA-27a:ZBTB10. Molecular Carcinogenesis, 52(8), 591–602. Portico. https://doi.org/10.1002/mc.21893

Marina Baretti

Baltimore, Maryland, United States of America
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Cancer Research
Cancer Research
Cancer Research
Other Research Interests (17)
Oncology
Pharmacology (medical)
Pharmacology
Hematology
Gastroenterology
And 12 more
About
Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.
Most Relevant Publications (14+)

57 total publications

The role of epigenetic therapies in colorectal cancer

Current Problems in Cancer / Nov 01, 2018

Baretti, M., & Azad, N. S. (2018). The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 42(6), 530–547. https://doi.org/10.1016/j.currproblcancer.2018.03.001

KRAS mutation in lung metastases from colorectal cancer: prognostic implications

Cancer Medicine / Dec 29, 2015

Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., Malesci, A., Alloisio, M., Laghi, L., Santoro, A., & Rimassa, L. (2015). <scp>KRAS</scp> mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 5(2), 256–264. Portico. https://doi.org/10.1002/cam4.592

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

JCO Precision Oncology / Jun 01, 2022

Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khouiery, A. B., Hockenberry, A. J., Lau, D., Lesinski, G. B., & Yarchoan, M. (2022). Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00510

Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.

Journal of Clinical Oncology / May 20, 2018

Baretti, M., Durham, J. N., Walker, R., Mitcheltree, A.-L., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2018). Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology, 36(15_suppl), TPS4151–TPS4151. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4151

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Cancer Cell / Mar 01, 2022

Baretti, M., Kim, A. K., & Anders, R. A. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 40(3), 252–254. https://doi.org/10.1016/j.ccell.2022.02.017

Precision Cancer Trials With Immunomodulatory Agents

The Cancer Journal / Jul 01, 2019

Baretti, M., & Azad, N. S. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal, 25(4), 287–295. https://doi.org/10.1097/ppo.0000000000000390

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Cancers / Oct 30, 2022

Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347. https://doi.org/10.3390/cancers14215347

Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment

Cancer Research / Apr 04, 2023

Kamdar, Z., Lopez-Vidal, T., Howe, K., Munjal, K., Saeed, A., Zabransky, D., Shu, D., Longway, G., Kartalia, E., Leatherman, J., Mohan, A., Khare, P., Zhang, C., Le, A., Pearce, E., Furth, M., Baretti, M., Leone, R., Jaffee, E., & Yarchoan, M. (2023). Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment. Cancer Research, 83(7_Supplement), 3679–3679. https://doi.org/10.1158/1538-7445.am2023-3679

Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer.

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Fu, W., Wang, H., Anders, R. A., Azad, N. S., & Zhu, Q. (2019). Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. Journal of Clinical Oncology, 37(4_suppl), 570–570. https://doi.org/10.1200/jco.2019.37.4_suppl.570

The impact of the immune microenvironment in patients with GEP-NETs.

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Zhu, Q., Zahurak, M., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2019). The impact of the immune microenvironment in patients with GEP-NETs. Journal of Clinical Oncology, 37(4_suppl), 267–267. https://doi.org/10.1200/jco.2019.37.4_suppl.267

Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

Journal of Clinical Oncology / May 20, 2010

Vasile, E., Caponi, S., Lucchesi, M., Del Chiaro, M., Funel, N., Ginocchi, L., Campani, D., Falcone, A., Boggi, U., & Mosca, F. (2010). Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Journal of Clinical Oncology, 28(15_suppl), e14605–e14605. https://doi.org/10.1200/jco.2010.28.15_suppl.e14605

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

Cancer Biology &amp; Therapy / Apr 13, 2018

Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology &amp; Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

Gastric Cancer / Aug 16, 2016

Personeni, N., Baretti, M., Bozzarelli, S., Spaggiari, P., Rubino, L., Tronconi, M. C., Fumagalli Romario, U., Rosati, R., Giordano, L., Roncalli, M., Santoro, A., & Rimassa, L. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 20(3), 428–437. https://doi.org/10.1007/s10120-016-0625-1

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice

Lung Cancer / May 01, 2016

Metro, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Mountzios, G., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., & Toschi, L. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 95, 82–87. https://doi.org/10.1016/j.lungcan.2016.03.006

Ramy Ayoub

Ph.D. Candidate, University of Toronto | SickKids Hospital
Most Relevant Research Interests
Cancer Research
Other Research Interests (15)
neuro-oncology
mouse imaging
cancer therapy
normal tissue toxicity
General Biochemistry, Genetics and Molecular Biology
And 10 more
About
Ramy Ayoub is a PhD candidate at the University of Toronto in the department of Medical Biophysics. His research focuses on the development of treatment strategies to limit long-term negative complications in brain tumour survivors treated with radiation therapy. Ramy addresses his thesis work by conducting genetic, pharmacological, and neuroimaging studies on mouse models for paediatric radiotherapy. Ramy has authored numerous scientific publications and is a recipient of several awards, including the Brain Star award for excellence in Canadian research. Ramy has passion for advancing science innovation through collaborative efforts across academia and industry.
Most Relevant Publications (1+)

7 total publications

QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

Timothy Sears

PhD student, Bioinformatics, UC San Diego
Most Relevant Research Interests
Cancer Research
Cancer Research
Other Research Interests (14)
bioinformatics
cancer genomics
immunotherapy
General Biochemistry, Genetics and Molecular Biology
General Medicine
And 9 more
About
3rd Year PhD student at UC San Diego with large corporate & high-level academic experience.
Most Relevant Publications (3+)

7 total publications

Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis

Clinical Cancer Research / May 02, 2023

Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, H.-C., Wang, D. S., Hwang, G. L., Ganjoo, K. N., & Moding, E. J. (2023). Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis. Clinical Cancer Research, 29(14), 2612–2620. https://doi.org/10.1158/1078-0432.ccr-23-0250

Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response

Cancer Research / Apr 04, 2023

Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G. P., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradic, M., Torres, I. A., Oladipo, E., New, C., Kenney, D. E., Avedian, R. S., Steffner, R. J., Binkley, M. S., Mohler, D. G., Tap, W. D., D’Angelo, S. P., … Moding, E. J. (2023). Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response. Cancer Research, 83(7_Supplement), 5960–5960. https://doi.org/10.1158/1538-7445.am2023-5960

Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response

Cancer Research / Jun 15, 2022

Pagadala, M., Wu, V., Pérez-Guijarro, E., Kim, H., Castro, A., Talwar, J., Gonzalez-Colin, C., Cao, S., Schmiedel, B. J., Sears, T., Goudarzi, S., Kirani, D., Salem, R. M., Morris, G. P., Harismendy, O., Patel, S. P., Mesirov, J. P., Zanetti, M., Day, C.-P., … Carter, H. (2022). Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response. Cancer Research, 82(12_Supplement), 3825–3825. https://doi.org/10.1158/1538-7445.am2022-3825

Katelyn Katelyn Masiuk

Co-Founder and CSO at Immunovec
Most Relevant Research Interests
Cancer Research
Cancer Research
Other Research Interests (25)
Cell Biology
Genetics
Molecular Medicine
Genetics
Molecular Biology
And 20 more
About
Katelyn Masiuk is the co-founder and Chief Scientific Officer of ImmunoVec. She is also a medical student in the MSTP program at UCLA. Her research interests include immunology and virology.
Most Relevant Publications (2+)

13 total publications

Pharmacologic Inhibition of ALK5 Causes Selective Induction of Terminal Differentiation in Mouse Keratinocytes Expressing Oncogenic HRAS

Molecular Cancer Research / Jun 01, 2011

Markell, L. M., Masiuk, K. E., Blazanin, N., & Glick, A. B. (2011). Pharmacologic Inhibition of ALK5 Causes Selective Induction of Terminal Differentiation in Mouse Keratinocytes Expressing Oncogenic HRAS. Molecular Cancer Research, 9(6), 746–756. https://doi.org/10.1158/1541-7786.mcr-11-0112

Use of a TGFβ type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFβ signaling in tumor promotion and progression

Carcinogenesis / Sep 17, 2010

Mordasky Markell, L., Pérez-Lorenzo, R., Masiuk, K. E., Kennett, M. J., & Glick, A. B. (2010). Use of a TGFβ type I receptor inhibitor in mouse skin carcinogenesis reveals a dual role for TGFβ signaling in tumor promotion and progression. Carcinogenesis, 31(12), 2127–2135. https://doi.org/10.1093/carcin/bgq191

Amir Manbachi

Co-director and Founder of the Johns Hopkins HEPIUS Innovation Lab
Most Relevant Research Interests
Cancer Research
Other Research Interests (56)
Biomedical Engineering
Engineering Design
Medical Devices
Ultrasound
Neurosurgery
And 51 more
Most Relevant Publications (3+)

92 total publications

Reusable Core Needle Biopsy Device for Low-Resource Settings

Journal of Global Oncology / Oct 01, 2018

Callanan, M., Zawicki, V., Hinson, L., Lee, M., Triantis, S., Manbachi, A., & Harvey, S. (2018). Reusable Core Needle Biopsy Device for Low-Resource Settings. Journal of Global Oncology, 4(Supplement 3), 47s–47s. https://doi.org/10.1200/jgo.18.10550

Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models

Frontiers in Oncology / Feb 16, 2023

Thombre, R., Mess, G., Kempski Leadingham, K. M., Kapoor, S., Hersh, A., Acord, M., Kaovasia, T., Theodore, N., Tyler, B., & Manbachi, A. (2023). Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1072780

Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier

Cancers / Oct 08, 2022

Hersh, A. M., Bhimreddy, M., Weber-Levine, C., Jiang, K., Alomari, S., Theodore, N., Manbachi, A., & Tyler, B. M. (2022). Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. Cancers, 14(19), 4920. https://doi.org/10.3390/cancers14194920

Dona SLEIMAN

Paris
After completing my BS in Biochemistry in Beirut, I pursued a master’s degree in Genetics followed by a Master 2 degree in Molecular Engineering. I received my PhD in Biochemistry and Biophysics in 2013 at Paris Descartes University with the highest honors & Committee Praise. Throughout my thesis and post-doctoral experience, I have studied different aspects of protein/nucleic acid interactions using several biophysical techniques.
Most Relevant Research Interests
Cancer Research
Other Research Interests (8)
synthetic biology, Protein design, Biochemistry
Multidisciplinary
Infectious Diseases
Virology
Genetics (clinical)
And 3 more
Most Relevant Publications (2+)

4 total publications

Initiation of HIV-1 reverse transcription and functional role of nucleocapsid-mediated tRNA/viral genome interactions

Virus Research / Nov 01, 2012

Sleiman, D., Goldschmidt, V., Barraud, P., Marquet, R., Paillart, J.-C., & Tisné, C. (2012). Initiation of HIV-1 reverse transcription and functional role of nucleocapsid-mediated tRNA/viral genome interactions. Virus Research, 169(2), 324–339. https://doi.org/10.1016/j.virusres.2012.06.006

Cyclic di-AMP regulation of osmotic homeostasis is essential in Group B Streptococcus

PLOS Genetics / Apr 16, 2018

Devaux, L., Sleiman, D., Mazzuoli, M.-V., Gominet, M., Lanotte, P., Trieu-Cuot, P., Kaminski, P.-A., & Firon, A. (2018). Cyclic di-AMP regulation of osmotic homeostasis is essential in Group B Streptococcus. PLOS Genetics, 14(4), e1007342. https://doi.org/10.1371/journal.pgen.1007342

Olivier Saulnier

The Hospital for Sick Children
Most Relevant Research Interests
Cancer Research
Other Research Interests (17)
Bioinformatics - single-cell omics
Neurology (clinical)
General Biochemistry, Genetics and Molecular Biology
Oncology
General Physics and Astronomy
And 12 more
Most Relevant Publications (5+)

25 total publications

EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA

Neuro-Oncology / Dec 01, 2020

Kumar, S., Michealraj, A., Kim, L., Rich, J., & Taylor, M. (2020). EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA. Neuro-Oncology, 22(Supplement_3), iii318–iii318. https://doi.org/10.1093/neuonc/noaa222.185

MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA

Neuro-Oncology / Jun 01, 2023

Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254

BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA

Neuro-Oncology / Jun 01, 2023

Llaguno, S. A., Nazarenko, I., Chen, Y., Sun, D., Gudenas, B., Saulnier, O., Rocca, G. L., Pedraza, A., Burns, D., Bale, T., Ventura, A., Northcott, P., Taylor, M., & Parada, L. (2023). BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i11–i11. https://doi.org/10.1093/neuonc/noad073.042

Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA

Clinical Cancer Research / Sep 15, 2022

Delattre, O., Vibert, J., Saulnier, O., & Waterfall, J. (2022). Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA. Clinical Cancer Research, 28(18_Supplement), IA009–IA009. https://doi.org/10.1158/1557-3265.sarcomas22-ia009

The LIN28B–let‐7–PBK pathway is essential for group 3 medulloblastoma tumor growth and survival

Molecular Oncology / Aug 07, 2023

Shahab, S. W., Roggeveen, C. M., Sun, J., Kunhiraman, H., McSwain, L. F., Juraschka, K., Kumar, S. A., Saulnier, O., Taylor, M. D., Schniederjan, M., Schnepp, R. W., MacDonald, T. J., & Kenney, A. M. (2023). The <scp>LIN28B</scp>–let‐7–<scp>PBK</scp> pathway is essential for group 3 medulloblastoma tumor growth and survival. Molecular Oncology. Portico. https://doi.org/10.1002/1878-0261.13477

AMAN SHARMA

Postdoctoral Research Fellow, Memorial Sloan Kettering Cancer Center.
Most Relevant Research Interests
Cancer Research
Other Research Interests (11)
nuclear hormone receptors
DNA damage and repair
R loops
G quadruplex
homologous recombination
And 6 more
Most Relevant Publications (3+)

8 total publications

Inter-Individual Variation in Response to Estrogen in Human Breast Explants

Journal of Mammary Gland Biology and Neoplasia / Mar 01, 2020

Dunphy, K. A., Black, A. L., Roberts, A. L., Sharma, A., Li, Z., Suresh, S., Browne, E. P., Arcaro, K. F., Ser-Dolansky, J., Bigelow, C., Troester, M. A., Schneider, S. S., Makari-Judson, G., Crisi, G. M., & Jerry, D. J. (2020). Inter-Individual Variation in Response to Estrogen in Human Breast Explants. Journal of Mammary Gland Biology and Neoplasia, 25(1), 51–68. https://doi.org/10.1007/s10911-020-09446-3

Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women

Cancer Research / Feb 15, 2022

Dunphy, K. A., Sharma, A., Majhi, P., Schneider, S. S., Crisi, G. M., Makari-Judson, G., & Jerry, D. J. (2022). Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women. Cancer Research, 82(4_Supplement), P1-07-10-P1-07–10. https://doi.org/10.1158/1538-7445.sabcs21-p1-07-10

Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage

Cancer Research / Jul 01, 2018

Dunphy, K. A., Majhi, P. D., Sharma, A., Roberts, A. L., Daniele, E. A., Schneider, S. S., & Jerry, D. J. (2018). Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage. Cancer Research, 78(13_Supplement), 3750–3750. https://doi.org/10.1158/1538-7445.am2018-3750

Example cancer research projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on cancer research?

Development of Targeted Therapies

An academic researcher in Cancer Research can collaborate with a pharmaceutical company to develop targeted therapies for specific types of cancer. By leveraging their expertise in molecular biology and drug discovery, the researcher can contribute to the design and optimization of novel drugs that selectively target cancer cells while minimizing side effects.

Identification of Novel Biomarkers

A company specializing in diagnostic tools can collaborate with a Cancer Research expert to identify novel biomarkers for early cancer detection. The researcher can utilize their knowledge of cancer biology and molecular techniques to identify specific biomarkers that can be incorporated into diagnostic tests, enabling early intervention and improved patient outcomes.

Genomic Analysis for Personalized Medicine

By partnering with an academic researcher in Cancer Research, a biotech company can leverage genomic analysis to develop personalized medicine approaches. The researcher can analyze genomic data from patients to identify genetic mutations and variations that can inform treatment decisions, leading to more targeted and effective therapies.

Development of Immunotherapies

Collaboration between a pharmaceutical company and a Cancer Research expert can lead to the development of innovative immunotherapies. The researcher can contribute their knowledge of the immune system and cancer immunology to design and optimize immunotherapeutic approaches, enhancing the company's portfolio of cancer treatments.

Exploration of Combination Therapies

An academic researcher in Cancer Research can collaborate with a company to explore combination therapies for cancer treatment. By combining different drugs or treatment modalities, the researcher can help identify synergistic effects and optimize treatment regimens, potentially improving patient outcomes and expanding the company's treatment options.